BMS 813160

Drug Profile

BMS 813160

Alternative Names: BMS813160

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Pyrazoles; Triazines
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I/II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 18 Apr 2018 Bristol-Myers Squibb plans a phase I/II trial for Pancreatic cancer in the US , (NCT03496662)
  • 23 Aug 2017 Phase II development is ongoing for Diabetic nephropathies in USA, Canada, France, Denmark
  • 04 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer and Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (unspecified route) (NCT03184870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top